Noninvasive fetal blood group antigen genotyping serves as a diagnostic tool to predict the risk of hemolytic disease of the fetus and newborn in pregnancies of immunized women. In addition, fetal RHD genotyping is used as an antenatal screening to guide targeted use of immunoglobulin prophylaxis in non-immunized RhD negative, pregnant women. Based on testing of cell-free DNA extracted from maternal plasma, these noninvasive assays demonstrate high performance accuracies. Consequently, noninvasive fetal blood group antigen genotyping has become standard care in transfusion medicine.



Frederik Banch Clausen - Laboratory of Blood Genetics, Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark https://orcid.org/0000-0003-2487-5373

C Ellen van der Schoot - Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands https://orcid.org/0000-0002-8065-3540

  • Abstract viewed - 283 times
  • pdf downloaded - 196 times